[go: up one dir, main page]

ECSP18038868A - Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll - Google Patents

Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll

Info

Publication number
ECSP18038868A
ECSP18038868A ECIEPI201838868A ECPI201838868A ECSP18038868A EC SP18038868 A ECSP18038868 A EC SP18038868A EC IEPI201838868 A ECIEPI201838868 A EC IEPI201838868A EC PI201838868 A ECPI201838868 A EC PI201838868A EC SP18038868 A ECSP18038868 A EC SP18038868A
Authority
EC
Ecuador
Prior art keywords
toll
receptor agonist
antibody conjugates
type receptor
conjugates including
Prior art date
Application number
ECIEPI201838868A
Other languages
English (en)
Inventor
Cortez Alex
Hubert Geierstanger Bernhard
Kasibhatla Shailaja
Uno Tetsuo
Yao-Hsiang Wu Tom
Wang Xing
Z Hoffman Timothy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP18038868A publication Critical patent/ECSP18038868A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente, conjugados de anticuerpos que comprenden agonistas del receptor tipo toll y el uso de tales conjugados para el tratamiento de cáncer. En algunas modalidades, los conjugados comprenden anticuerpos anti-HER2
ECIEPI201838868A 2015-10-29 2018-05-21 Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll ECSP18038868A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562247896P 2015-10-29 2015-10-29

Publications (1)

Publication Number Publication Date
ECSP18038868A true ECSP18038868A (es) 2018-05-31

Family

ID=57227020

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201838868A ECSP18038868A (es) 2015-10-29 2018-05-21 Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll

Country Status (29)

Country Link
US (2) US10973826B2 (es)
EP (2) EP3368092B9 (es)
JP (2) JP6877420B2 (es)
KR (1) KR20180068989A (es)
CN (1) CN108430515B (es)
AR (1) AR106491A1 (es)
AU (1) AU2016347385B2 (es)
BR (1) BR112018007296A2 (es)
CA (1) CA3001482A1 (es)
CL (1) CL2018000920A1 (es)
CO (1) CO2018004315A2 (es)
CR (1) CR20180229A (es)
CU (1) CU24502B1 (es)
EA (1) EA201891040A1 (es)
EC (1) ECSP18038868A (es)
ES (1) ES2798649T3 (es)
IL (1) IL258483A (es)
MA (1) MA44334A (es)
MX (1) MX2018005289A (es)
PE (1) PE20181347A1 (es)
PH (1) PH12018500815A1 (es)
PL (1) PL3368092T3 (es)
PT (1) PT3368092T (es)
RU (1) RU2018119296A (es)
SG (1) SG11201802769RA (es)
TN (1) TN2018000112A1 (es)
TW (1) TW201722482A (es)
UY (1) UY36968A (es)
WO (1) WO2017072662A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874493T3 (es) * 2013-02-08 2021-11-05 Novartis Ag Sitios específicos para modificar anticuerpos para generar inmunoconjugados
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
JP2020511501A (ja) * 2016-12-13 2020-04-16 ボルト バイオセラピューティクス、インコーポレーテッド 抗体アジュバント複合体
AU2018227807B2 (en) 2017-02-28 2024-10-10 Seagen Inc. Cysteine mutated antibodies for conjugation
AR111651A1 (es) * 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
WO2018232088A1 (en) * 2017-06-16 2018-12-20 Eli Lilly And Company Engineered antibody compounds and conjugates thereof
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
JP7386536B2 (ja) 2017-08-22 2023-11-27 ダイナヴァックス テクノロジーズ コーポレイション アルキル鎖修飾イミダゾキノリンｔｌｒ７／８アゴニスト化合物およびその使用
US10722591B2 (en) 2017-11-14 2020-07-28 Dynavax Technologies Corporation Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
PE20211456A1 (es) 2018-02-28 2021-08-05 Hoffmann La Roche Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
KR20250078590A (ko) * 2018-09-06 2025-06-02 다이이찌 산쿄 가부시키가이샤 신규 고리형 디뉴클레오티드 유도체 및 그 항체 약물 콘쥬게이트
JP2022500414A (ja) * 2018-09-12 2022-01-04 シルバーバック セラピューティックス インコーポレイテッド 免疫刺激性コンジュゲートにより疾患を処置する方法および組成物
EP3873532A1 (en) * 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
CN119455003A (zh) * 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
WO2020190731A1 (en) * 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2020190734A1 (en) * 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting pd-l1
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP7706210B2 (ja) * 2019-06-10 2025-07-11 ストロ バイオファーマ インコーポレーテッド ５Ｈ－ピロロ［３，２－ｄ］ピリミジン－２，４－ジアミノ化合物およびその抗体コンジュゲート
EP3980080A1 (en) * 2019-06-10 2022-04-13 Sutro Biopharma, Inc. Immunomodulator antibody drug conjugates and uses thereof
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
WO2021154668A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097107A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company C3-substituted 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
JP7712942B2 (ja) 2020-01-27 2025-07-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
WO2021154666A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP7712941B2 (ja) 2020-01-27 2025-07-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
KR20220132590A (ko) * 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
EP4097108A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230131192A1 (en) 2020-01-27 2023-04-27 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
WO2021154663A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
CA3183993A1 (en) 2020-07-01 2022-01-06 Peter R. Baum Anti-asgr1 antibody conjugates and uses thereof
CN116322777A (zh) * 2020-08-04 2023-06-23 西吉隆医疗股份有限公司 杂芳基和杂环基化合物
CA3190606A1 (en) * 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
US20240124486A1 (en) 2020-09-27 2024-04-18 Shanghai Visonpharma Co., Ltd. Macrocyclic tlr7 agonist, preparation method therefor, pharmaceutical composition and use thereof
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
WO2022188740A1 (en) * 2021-03-08 2022-09-15 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody-immune agonist conjugate and applications thereof
CA3223304A1 (en) * 2021-06-17 2022-12-22 Minghui Pharmaceutical (Hangzhou) Limited Antitumor compound and its application
CA3223936A1 (en) 2021-06-28 2023-01-05 Ronald Christiaan Elgersma Conjugates comprising phosphoantigens and their use in therapy
WO2023076599A1 (en) 2021-10-29 2023-05-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
JP2025524965A (ja) * 2022-07-26 2025-08-01 ザイムワークス・ビーシー・インコーポレイテッド 免疫調節物質プリン誘導体化合物、その複合体、及びその使用の方法
EP4608453A1 (en) 2022-10-25 2025-09-03 Merck Sharp & Dohme LLC Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
TW202435916A (zh) * 2022-10-28 2024-09-16 美商美國禮來大藥廠 用於生物結合之自體水解順丁烯二酼亞胺
TW202434302A (zh) 2022-10-31 2024-09-01 日商安斯泰來製藥股份有限公司 包含類鐸受體７／８雙重促效劑化合物之抗體藥物複合體
KR20250128394A (ko) * 2022-11-30 2025-08-27 리제너론 파마슈티칼스 인코포레이티드 Tlr7 작용제 및 이의 항체-약물-접합체
IL321395A (en) 2022-12-14 2025-08-01 Merck Sharp & Dohme Llc Auristatin cargo-linkers, pharmaceutical compounds, and their uses
JP2026502845A (ja) 2022-12-22 2026-01-27 ビョンディス・ビー．ブイ． ホスホ抗原を含む新規なリンカー－薬物、新規な複合体及び治療におけるその使用
TW202521540A (zh) 2023-08-04 2025-06-01 法商賽諾菲公司 咪唑并[4,5-d]嗒𠯤化合物及其接合物、其製備、及其治療應用

Family Cites Families (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
CA1329119C (en) 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US20030232010A2 (en) 1988-03-29 2003-12-18 Immunomedics, Inc. Improved cytotoxic therapy
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5290540A (en) 1991-05-01 1994-03-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for treating infectious respiratory diseases
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP0530537B1 (en) 1991-08-12 1997-01-08 Takeda Chemical Industries, Ltd. Condensed pyrimidine derivatives, their production and use as antitumor agents
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP0889052B1 (en) 1992-09-15 2009-04-15 Ortho Diagnostic Systems Inc. Immunoreactive peptides from Epstein-Barr virus
US7326535B2 (en) 1993-09-15 2008-02-05 Ortho Diagnostic Systems Inc. Immunoreactive peptides from Epstein-Barr virus
US7060283B1 (en) 1992-09-15 2006-06-13 Ortho Diagnostic Systems, Inc. Immunoreactive peptides from Epstein-Barr virus
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
WO1995033752A1 (en) 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
WO1997039774A1 (en) 1996-04-23 1997-10-30 Novopharm Biotech, Inc. Human monoclonal antibody specific for melanoma-associated antigen and methods of use
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US7541020B2 (en) 1997-05-08 2009-06-02 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7063967B2 (en) 1997-05-08 2006-06-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US20030103984A1 (en) 1998-05-04 2003-06-05 Heinz Kohler Fusion proteins of biologically active peptides and antibodies
US6238667B1 (en) 1997-09-19 2001-05-29 Heinz Kohler Method of affinity cross-linking biologically active immunogenic peptides to antibodies
US20040185039A1 (en) 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US20090075339A1 (en) 1997-09-19 2009-03-19 Innexus Biotechnology International Limited Autophilic antibodies
US20050033033A1 (en) 1998-05-04 2005-02-10 Heinz Kohler Trans-membrane-antibody induced inhibition of apoptosis
US7569674B2 (en) 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP1073667A2 (en) 1998-04-28 2001-02-07 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US20090208418A1 (en) 2005-04-29 2009-08-20 Innexus Biotechnology Internaltional Ltd. Superantibody synthesis and use in detection, prevention and treatment of disease
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
EP1089712B1 (en) 1998-06-24 2003-05-02 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
CA2346448A1 (en) 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AU4591600A (en) 1999-05-05 2000-11-21 Aventis Pharma Limited Substituted bicyclic compounds
EP1210372B1 (en) 1999-07-29 2008-01-23 Medarex, Inc. Human monoclonal antibodies to her2/neu
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
DE10024069A1 (de) 2000-05-17 2001-12-13 Gluesenkamp Karl Heinz Konjugat auf der Basis einer heterobifunktionalen Brückenverbindung, die mit einem Immunmodulator und einer zellerkennenden Einheit substituiert ist
AU2001275072A1 (en) 2000-05-31 2001-12-11 The Scripps Research Institute Molecular marker for mitosis
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
AU2006216669A1 (en) 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
EP1461423B1 (en) 2001-12-03 2008-05-14 Amgen Fremont Inc. Antibody categorization based on binding characteristics
PL216224B1 (pl) 2002-02-01 2014-03-31 Ariad Pharmaceuticals Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie
JP4575667B2 (ja) 2002-03-08 2010-11-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬として有用な大環状化合物
US20030190308A1 (en) 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
US20060088542A1 (en) 2002-03-19 2006-04-27 Powdermed Limited Imidazoquinoline adjuvants for vaccines
US20030185835A1 (en) 2002-03-19 2003-10-02 Braun Ralph P. Adjuvant for vaccines
AU2003216852B2 (en) 2002-03-19 2008-09-11 Glaxo Group Limited Imidazoquinolineamines as adjuvants in HIV DNA vaccination
NZ573064A (en) 2002-04-04 2011-02-25 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
WO2003087131A2 (en) 2002-04-10 2003-10-23 Genentech, Inc Anti-her2 antibody variants
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
KR100485155B1 (ko) 2002-05-22 2005-04-22 주식회사 삼양제넥스 효소저항전분을 포함하는 면역활성 증강용 조성물
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
AU2003265276A1 (en) 2002-07-15 2004-02-02 The Trustees Of Princeton University Iap binding compounds
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
CA2495570C (en) 2002-08-15 2012-12-04 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
AU2003286692A1 (en) 2002-10-25 2004-05-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulation of dendritic cell function and other cellular responses mediated by defensin compositions
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
ZA200506202B (en) 2003-01-31 2006-10-25 Celldex Therapeutics Inc Antibody vaccine conjugates and uses therefor
WO2004071459A2 (en) 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
JP2006522122A (ja) 2003-03-05 2006-09-28 インネクサス バイオテクノロジー インコーポレイテッド 膜貫通抗体誘導型のアポトーシス阻害
WO2004091500A2 (en) 2003-04-10 2004-10-28 3M Innovative Properties Company Delivery of immune response modifier compounds
JP2007514644A (ja) 2003-04-10 2007-06-07 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応を向上させる方法および組成物
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
EP1643514B1 (en) 2003-06-27 2012-11-21 TDK Corporation R-t-b based permanent magnet
EP1653959B1 (en) 2003-08-14 2015-05-27 3M Innovative Properties Company Lipid-modified immune response modifiers
JP2007504145A (ja) 2003-08-25 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 免疫刺激性の組み合わせおよび治療
EP1658035A4 (en) 2003-08-25 2007-08-22 3M Innovative Properties Co ADMINISTRATION OF MODIFIERS OF IMMUNE RESPONSE
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP1668010A2 (en) 2003-10-01 2006-06-14 Taro Pharmaceuticals U.S.A., Inc. Method of preparing 4-amino-1h -imidazo(4,5- c )quinolines and acid addition salts thereof
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050175630A1 (en) 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
CN1950106A (zh) 2003-12-24 2007-04-18 莱顿大学医学中心 用作肿瘤特异性疫苗的合成蛋白质
CN1933847A (zh) 2004-01-16 2007-03-21 密歇根大学董事会 Smac肽模拟物及其应用
WO2005069894A2 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
US20060002941A1 (en) 2004-01-23 2006-01-05 Vievax Corp. Compositions comprising immune response altering agents and methods of use
US7968557B2 (en) 2004-02-14 2011-06-28 Novartis Ag Substituted pyrrolo[2,3-2]pyrimidines as protein kinase inhibitors
EP1740173A4 (en) 2004-03-23 2009-05-27 Genentech Inc AZABICYCLOOCTAN IAP INHIBITORS
SG152225A1 (en) 2004-04-07 2009-05-29 Novartis Ag Inhibitors of iap
WO2005110013A2 (en) 2004-04-09 2005-11-24 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
GEP20105024B (en) 2004-06-02 2010-06-25 Takeda Pharmaceuticals Co Fused heterocyclic compound
US20080113929A1 (en) 2004-06-08 2008-05-15 Coley Pharmaceutical Gmbh Abasic Oligonucleotide as Carrier Platform for Antigen and Immunostimulatory Agonist and Antagonist
RS53734B1 (sr) 2004-07-02 2015-06-30 Genentech Inc. Inhibitori iap
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
EA200700225A1 (ru) 2004-07-12 2008-02-28 Айдан Фармасьютикалз, Инк. Аналоги тетрапептида
JP5230865B2 (ja) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
KR20150043558A (ko) 2004-07-22 2015-04-22 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
WO2006026394A2 (en) 2004-08-27 2006-03-09 3M Innovative Properties Company Method of eliciting an immune response against hiv
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1809671B1 (en) 2004-11-09 2014-07-16 University Of Southern California CpG/antibody conjugate against cancer
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
KR20120127754A (ko) 2004-12-20 2012-11-23 제넨테크, 인크. Ｉａｐ의 피롤리딘 억제제
CN101500574A (zh) 2005-03-15 2009-08-05 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
US7976852B2 (en) 2005-04-26 2011-07-12 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
ES2481402T3 (es) 2005-07-21 2014-07-30 Ardea Biosciences, Inc. Inhibidores de N-(arilamino)sulfonamida de MEK
WO2008020827A2 (en) 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
CA2618681C (en) 2005-08-10 2015-10-27 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CN101379195B (zh) 2005-12-20 2012-05-09 艾德拉药物股份有限公司 含有不同长度回文片段的回文免疫调节性寡核苷酸(imotm)的免疫刺激活性
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
US20080031887A1 (en) 2006-06-30 2008-02-07 Joseph Lustgarten Conjugates for inducing targeted immune responses and methods of making and using same
US20090074711A1 (en) 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
DK2845866T3 (en) 2006-10-27 2017-07-10 Genentech Inc Antibodies and immunoconjugates and their applications
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
RU2491276C2 (ru) 2007-04-30 2013-08-27 Дженентек, Инк. Ингибиторы iap
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
WO2009002939A2 (en) 2007-06-23 2008-12-31 Innexus Biotechnology International Limited Autophilic antibodies
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
MY188455A (en) 2007-10-19 2021-12-09 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
MX2010005783A (es) 2007-11-27 2010-08-10 Ablynx Nv Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
EP2244738B1 (en) 2008-01-25 2020-03-04 Gavish-Galilee Bio Applications Ltd Targeting of innate immune response to tumour site
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
CA2714177A1 (en) 2008-02-06 2009-08-13 Novartis Ag Pyrrolo [2,3-d] pyridines and use thereof as tyrosine kinase inhibitors
ES2639857T3 (es) 2008-02-11 2017-10-30 Cure Tech Ltd. Anticuerpos monoclonales para el tratamiento del tumor
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8802093B2 (en) 2008-04-02 2014-08-12 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same
JP6192891B2 (ja) * 2008-05-02 2017-09-06 ノバルティス アーゲー 改善されたフィブロネクチンベースの結合分子およびそれらの使用
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
EA201170375A1 (ru) 2008-08-25 2012-03-30 Эмплиммьюн, Инк. Антагонисты pd-1 и способы их применения
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
SMT202500126T1 (it) 2008-12-09 2025-05-12 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
EP2451838A1 (en) 2009-07-09 2012-05-16 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Stabilized immunoglobulin constant domains
TR201804897T4 (tr) 2009-10-07 2018-06-21 Macrogenics Inc Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
PL2330131T3 (pl) 2009-12-07 2015-05-29 Fundacio Privada Inst Catalana De Recerca I Estudis Avancants Przeciwciała przeciwko CTF-611, skróconemu wariantowi HER2
EP2513148B1 (en) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
WO2011130580A1 (en) 2010-04-15 2011-10-20 Alper Biotech, Llc Monoclonal antibodies against her2 antigens, and uses therefor
US20130137709A1 (en) 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
JP2013166700A (ja) 2010-06-02 2013-08-29 Dainippon Sumitomo Pharma Co Ltd 新規４，５−縮環ピリミジン誘導体
EP2579897A1 (en) 2010-06-08 2013-04-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
MX342164B (es) 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
JP2013535508A (ja) 2010-08-13 2013-09-12 ベイラー リサーチ インスティテュート 抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント
US20120321694A1 (en) 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
AR085633A1 (es) 2011-03-08 2013-10-16 Baylor Res Inst Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
EP2570125A1 (en) 2011-09-16 2013-03-20 Almirall, S.A. Ep1 receptor ligands
EP2794653B1 (en) 2011-12-23 2019-03-13 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2013179174A1 (en) 2012-05-29 2013-12-05 Koninklijke Philips N.V. Lighting arrangement
CN104334576B (zh) 2012-06-04 2019-02-19 诺华股份有限公司 位点特异性标记方法及由此产生的分子
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
TR201807076T4 (tr) * 2012-10-10 2018-06-21 Janssen Sciences Ireland Uc Viral enfeksiyonların ve diğer hastalıkların tedavisine yönelik pirolo[3,2-d]pirimidin derivatları.
JP6408480B2 (ja) * 2012-11-30 2018-10-17 ノバルティス アーゲー ジスルフィドを含むタンパク質から複合体を調製する方法
ES2874493T3 (es) 2013-02-08 2021-11-05 Novartis Ag Sitios específicos para modificar anticuerpos para generar inmunoconjugados
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
UY35397A (es) 2013-03-12 2014-10-31 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
JP2016516035A (ja) 2013-03-15 2016-06-02 ノバルティス アーゲー 細胞増殖阻害剤およびそれらのコンジュゲート
CN105007950B (zh) * 2013-03-15 2019-01-15 诺华股份有限公司 抗体药物缀合物
JP6453855B2 (ja) 2013-05-18 2019-01-16 アドゥロ バイオテック，インク． 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法
CN109369643B (zh) 2013-06-27 2021-05-18 爱尔兰詹森科学公司 用于治疗病毒感染和其他疾病的吡咯并[3,2-d]嘧啶衍生物
KR20160088429A (ko) 2013-11-26 2016-07-25 노파르티스 아게 케톤-변형된 폴리펩티드에 대한 옥심 접합을 위한 방법
EP3092254A4 (en) 2014-01-10 2017-09-20 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating her2 positive tumors
AU2015209277B2 (en) * 2014-01-22 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
WO2015138615A2 (en) 2014-03-12 2015-09-17 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
EP3129373B1 (en) 2014-04-11 2021-09-01 Taipei Medical University Histone deacetylase inhibitors
NZ724878A (en) * 2014-05-01 2019-03-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
ES2877050T3 (es) 2014-05-01 2021-11-16 Novartis Ag Compuestos y composiciones como agonistas del receptor 7 de tipo toll
MX2016016515A (es) 2014-06-13 2017-04-27 Novartis Ag Derivados de auristatina y conjugados de los mismos.
CA2954446A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN112546230A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CA2955445A1 (en) 2014-07-17 2016-01-21 Brian J. Czerniecki Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3
JP6967963B2 (ja) 2014-07-17 2021-11-17 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. 複数用量注射準備済樹状細胞ワクチンの製造ならびにｈｅｒ２およびｈｅｒ３を遮断するための併用療法
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
EP3177321B1 (en) 2014-08-08 2020-11-25 Oncoquest Pharmaceuticals Inc. Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy of cancer
CN106661034B (zh) 2014-08-15 2019-11-29 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
MA41538A (fr) 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
WO2016071856A1 (en) 2014-11-06 2016-05-12 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
CN104650228B (zh) 2014-11-26 2017-11-28 嘉和生物药业有限公司 一种全人源her2抗体、其编码基因及应用
SG11201704512PA (en) 2014-12-08 2017-07-28 Hoffmann La Roche 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
JP6313530B1 (ja) 2015-01-16 2018-04-18 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 標的化成分及びエフェクター成分を有する分子構築物
TWI614030B (zh) 2015-05-20 2018-02-11 免疫功坊股份有限公司 具有標的部分及效應部分的分子構建體
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN115300640A (zh) 2015-08-10 2022-11-08 杭州多禧生物科技有限公司 新型连接体及其用于药物和生物分子的特异性偶联
KR20240099511A (ko) 2015-08-24 2024-06-28 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
KR102112192B1 (ko) 2015-11-05 2020-05-19 치아타이 티안큉 파마수티컬 그룹 주식회사 Tlr7 효능제로서의 7-(티아졸-5-일)피롤로피리미딘 화합물
US11129910B2 (en) 2016-02-04 2021-09-28 Hangzhou Dac Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
CN107043379A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途

Also Published As

Publication number Publication date
CR20180229A (es) 2018-08-24
CU20180033A7 (es) 2018-09-05
EP3368092B9 (en) 2020-07-29
US20170121421A1 (en) 2017-05-04
IL258483A (en) 2018-05-31
US10973826B2 (en) 2021-04-13
JP2021100931A (ja) 2021-07-08
PH12018500815A1 (en) 2018-10-01
US20210346387A1 (en) 2021-11-11
EP3368092A1 (en) 2018-09-05
CA3001482A1 (en) 2017-05-04
SG11201802769RA (en) 2018-05-30
MX2018005289A (es) 2018-06-22
HK1257776A1 (en) 2019-10-25
CN108430515A (zh) 2018-08-21
PE20181347A1 (es) 2018-08-22
JP2018534297A (ja) 2018-11-22
PT3368092T (pt) 2020-06-18
JP6877420B2 (ja) 2021-05-26
MA44334A (fr) 2018-09-05
CO2018004315A2 (es) 2018-07-19
EA201891040A1 (ru) 2018-10-31
TW201722482A (zh) 2017-07-01
EP3368092B1 (en) 2020-03-25
CU24502B1 (es) 2021-04-07
EP3797797A1 (en) 2021-03-31
AR106491A1 (es) 2018-01-17
RU2018119296A (ru) 2019-11-29
UY36968A (es) 2017-05-31
ES2798649T3 (es) 2020-12-11
BR112018007296A2 (pt) 2018-10-23
RU2018119296A3 (es) 2020-02-25
TN2018000112A1 (en) 2019-10-04
WO2017072662A1 (en) 2017-05-04
CL2018000920A1 (es) 2019-03-15
CN108430515B (zh) 2021-11-12
KR20180068989A (ko) 2018-06-22
PL3368092T3 (pl) 2020-09-07
AU2016347385B2 (en) 2019-09-19
AU2016347385A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
ECSP18038868A (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
CL2019003050A1 (es) Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinación.
CL2018003406A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
CL2018002878A1 (es) Composiciones y anticuerpos anti-tim-3.
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CO2018001624A2 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
AR113224A1 (es) Conjugados de anticuerpo que comprenden un agonista de sting
AR114284A1 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
CO2018005433A2 (es) Conjugados de fármaco de anticuerpo her2 específicos de sitio
MX2023005880A (es) Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
CL2017001217A1 (es) Conjugados de droga de anticuerpos.
BR112015010436A2 (pt) Anticorpos anti-notch3 e conjugados anticorpo-fármaco
CU20150128A7 (es) Conjugados fármaco-anticuerpo
CL2018003045A1 (es) Semaglutida en afecciones cardiovasculares.
ECSP20082970A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
CL2019003557A1 (es) Anticuerpos anti-trkb.
CL2018002050A1 (es) Conjugados anticuerpo-fármaco dirigidos a gcc.
CO2017010692A2 (es) Construcciones de calicheamicina y sus métodos de uso
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.
AR108690A1 (es) Anticuerpos contra el miembro 21 de la superfamilia del receptor del factor de necrosis tumoral (anti-tnfrsf21) y métodos de uso de los mismos